25 XP   0   0   10

Karuna Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Karuna Therapeutics Inc together

PenkeI guess you are interested in Karuna Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Karuna Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Karuna Therapeutics Inc

I send you an email if I find something interesting about Karuna Therapeutics Inc.

Quick analysis of Karuna Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Karuna Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$32.83
Expected worth in 1 year
$36.18
How sure are you?
28.6%

+ What do you gain per year?

Total Gains per Share
$3.35
Return On Investment
1.0%

For what price can you sell your share?

Current Price per Share
$329.83
Expected price per share
$296.06 - $
How sure are you?
50%

1. Valuation of Karuna Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$329.83

Intrinsic Value Per Share

$-155.66 - $-184.79

Total Value Per Share

$-122.83 - $-151.96

2. Growth of Karuna Therapeutics Inc (5 min.)




Is Karuna Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$1.2b$792.3m$578.7m42.2%

How much money is Karuna Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$105.5m-$66.9m-$38.5m-36.6%
Net Profit Margin-3,290.6%-21,979.7%--

How much money comes from the company's main activities?

3. Financial Health of Karuna Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#47 / 1016

Most Revenue
#612 / 1016

Most Profit
#974 / 1016

Most Efficient
#883 / 1016

What can you expect buying and holding a share of Karuna Therapeutics Inc? (5 min.)

Welcome investor! Karuna Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Karuna Therapeutics Inc.

What can you expect buying and holding a share of Karuna Therapeutics Inc?

First you should know what it really means to hold a share of Karuna Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Karuna Therapeutics Inc is $329.83. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Karuna Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Karuna Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $32.83. Based on the TTM, the Book Value Change Per Share is $0.84 per quarter. Based on the YOY, the Book Value Change Per Share is $4.09 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Karuna Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-2.98-0.9%-2.84-0.9%-1.81-0.5%-1.26-0.4%-1.22-0.4%
Usd Book Value Change Per Share-1.78-0.5%0.840.3%4.091.2%1.520.5%1.560.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-1.78-0.5%0.840.3%4.091.2%1.520.5%1.560.5%
Usd Price Per Share316.51-221.02-168.68-126.02-120.02-
Price to Earnings Ratio-26.56--19.49--22.98--32.54--30.99-
Price-to-Total Gains Ratio-177.59--86.41--79.83--137.41--137.41-
Price to Book Ratio9.64-6.26-9.13-6.47-6.16-
Price-to-Total Gains Ratio-177.59--86.41--79.83--137.41--137.41-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share329.83
Number of shares3
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.841.52
Usd Total Gains Per Share0.841.52
Gains per Quarter (3 shares)2.514.57
Gains per Year (3 shares)10.0518.26
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101000188
20201003726
30302005544
40403007362
50504009180
606050011098
7070600128116
8080700146134
9090800164152
100101900183170

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.021.00.00.0%0.021.00.00.0%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%6.015.00.028.6%6.015.00.028.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.021.00.0%0.00.021.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%6.015.00.028.6%6.015.00.028.6%

Fundamentals of Karuna Therapeutics Inc

About Karuna Therapeutics Inc

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-11 12:52:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Karuna Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Karuna Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Karuna Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Karuna Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-3,290.6%+3,290.6%
TTM-3,290.6%YOY-21,979.7%+18,689.1%
TTM-3,290.6%5Y-5,057.8%+1,767.2%
5Y-5,057.8%10Y-4,817.0%-240.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--197.2%+197.2%
TTM-3,290.6%-210.4%-3,080.2%
YOY-21,979.7%-279.3%-21,700.4%
5Y-5,057.8%-436.8%-4,621.0%
10Y-4,817.0%-599.3%-4,217.7%
1.1.2. Return on Assets

Shows how efficient Karuna Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Karuna Therapeutics Inc to the Biotechnology industry mean.
  • -8.5% Return on Assets means that Karuna Therapeutics Inc generated $-0.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Karuna Therapeutics Inc:

  • The MRQ is -8.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -7.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.5%TTM-7.5%-1.1%
TTM-7.5%YOY-9.8%+2.4%
TTM-7.5%5Y-7.7%+0.3%
5Y-7.7%10Y-7.8%+0.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.5%-13.6%+5.1%
TTM-7.5%-12.9%+5.4%
YOY-9.8%-11.9%+2.1%
5Y-7.7%-14.2%+6.5%
10Y-7.8%-16.2%+8.4%
1.1.3. Return on Equity

Shows how efficient Karuna Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Karuna Therapeutics Inc to the Biotechnology industry mean.
  • -9.1% Return on Equity means Karuna Therapeutics Inc generated $-0.09 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Karuna Therapeutics Inc:

  • The MRQ is -9.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -7.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.1%TTM-7.8%-1.3%
TTM-7.8%YOY-10.3%+2.5%
TTM-7.8%5Y-6.3%-1.5%
5Y-6.3%10Y-6.4%+0.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.1%-17.0%+7.9%
TTM-7.8%-16.1%+8.3%
YOY-10.3%-15.4%+5.1%
5Y-6.3%-20.0%+13.7%
10Y-6.4%-21.1%+14.7%

1.2. Operating Efficiency of Karuna Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Karuna Therapeutics Inc is operating .

  • Measures how much profit Karuna Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Karuna Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Karuna Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-4,181.7%+4,181.7%
TTM-4,181.7%YOY-25,710.5%+21,528.8%
TTM-4,181.7%5Y-5,982.3%+1,800.6%
5Y-5,982.3%10Y-5,697.4%-284.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--286.1%+286.1%
TTM-4,181.7%-224.4%-3,957.3%
YOY-25,710.5%-288.4%-25,422.1%
5Y-5,982.3%-475.2%-5,507.1%
10Y-5,697.4%-624.7%-5,072.7%
1.2.2. Operating Ratio

Measures how efficient Karuna Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Karuna Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM42.067-42.067
TTM42.067YOY258.750-216.683
TTM42.0675Y60.252-18.185
5Y60.25210Y57.382+2.869
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.997-2.997
TTM42.0673.247+38.820
YOY258.7503.766+254.984
5Y60.2525.675+54.577
10Y57.3827.857+49.525

1.3. Liquidity of Karuna Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Karuna Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 19.31 means the company has $19.31 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Karuna Therapeutics Inc:

  • The MRQ is 19.306. The company is very able to pay all its short-term debts. +2
  • The TTM is 36.136. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ19.306TTM36.136-16.830
TTM36.136YOY27.726+8.410
TTM36.1365Y56.558-20.422
5Y56.55810Y59.307-2.748
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ19.3063.930+15.376
TTM36.1364.251+31.885
YOY27.7265.436+22.290
5Y56.5586.045+50.513
10Y59.3076.363+52.944
1.3.2. Quick Ratio

Measures if Karuna Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Karuna Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 34.42 means the company can pay off $34.42 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Karuna Therapeutics Inc:

  • The MRQ is 34.416. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 61.889. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ34.416TTM61.889-27.473
TTM61.889YOY43.810+18.079
TTM61.8895Y87.292-25.403
5Y87.29210Y88.770-1.478
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ34.4163.629+30.787
TTM61.8894.065+57.824
YOY43.8105.397+38.413
5Y87.2925.993+81.299
10Y88.7706.277+82.493

1.4. Solvency of Karuna Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Karuna Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Karuna Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.06 means that Karuna Therapeutics Inc assets are financed with 6.1% credit (debt) and the remaining percentage (100% - 6.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Karuna Therapeutics Inc:

  • The MRQ is 0.061. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.040. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.061TTM0.040+0.021
TTM0.040YOY0.044-0.004
TTM0.0405Y0.180-0.140
5Y0.18010Y0.172+0.008
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0610.332-0.271
TTM0.0400.334-0.294
YOY0.0440.268-0.224
5Y0.1800.366-0.186
10Y0.1720.390-0.218
1.4.2. Debt to Equity Ratio

Measures if Karuna Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Karuna Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 6.5% means that company has $0.07 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Karuna Therapeutics Inc:

  • The MRQ is 0.065. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.042. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.065TTM0.042+0.023
TTM0.042YOY0.046-0.004
TTM0.0425Y0.029+0.013
5Y0.02910Y0.028+0.001
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0650.381-0.316
TTM0.0420.390-0.348
YOY0.0460.334-0.288
5Y0.0290.434-0.405
10Y0.0280.466-0.438

2. Market Valuation of Karuna Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Karuna Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Karuna Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -26.56 means the investor is paying $-26.56 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Karuna Therapeutics Inc:

  • The EOD is -27.673. Based on the earnings, the company is expensive. -2
  • The MRQ is -26.555. Based on the earnings, the company is expensive. -2
  • The TTM is -19.491. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-27.673MRQ-26.555-1.118
MRQ-26.555TTM-19.491-7.065
TTM-19.491YOY-22.983+3.493
TTM-19.4915Y-32.537+13.046
5Y-32.53710Y-30.988-1.549
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-27.673-2.315-25.358
MRQ-26.555-2.560-23.995
TTM-19.491-2.664-16.827
YOY-22.983-4.122-18.861
5Y-32.537-6.258-26.279
10Y-30.988-6.108-24.880
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Karuna Therapeutics Inc:

  • The EOD is -28.159. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -27.022. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -22.660. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-28.159MRQ-27.022-1.137
MRQ-27.022TTM-22.660-4.362
TTM-22.660YOY-28.531+5.871
TTM-22.6605Y-42.426+19.766
5Y-42.42610Y-40.406-2.020
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-28.159-3.067-25.092
MRQ-27.022-3.251-23.771
TTM-22.660-3.545-19.115
YOY-28.531-5.595-22.936
5Y-42.426-8.315-34.111
10Y-40.406-8.708-31.698
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Karuna Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 9.64 means the investor is paying $9.64 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Karuna Therapeutics Inc:

  • The EOD is 10.045. Based on the equity, the company is expensive. -2
  • The MRQ is 9.640. Based on the equity, the company is overpriced. -1
  • The TTM is 6.256. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD10.045MRQ9.640+0.406
MRQ9.640TTM6.256+3.384
TTM6.256YOY9.129-2.874
TTM6.2565Y6.470-0.214
5Y6.47010Y6.162+0.308
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD10.0451.905+8.140
MRQ9.6402.111+7.529
TTM6.2562.095+4.161
YOY9.1292.836+6.293
5Y6.4703.443+3.027
10Y6.1623.794+2.368
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Karuna Therapeutics Inc.

3.1. Institutions holding Karuna Therapeutics Inc

Institutions are holding 86.324% of the shares of Karuna Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30FMR Inc14.82320.08265650167335790.5979
2023-12-31Capital Research & Mgmt Co - Division 311.08980.299942271022364915.9262
2023-09-30Vanguard Group Inc8.40460.013332035851056863.4115
2023-12-31T. Rowe Price Investment Management,Inc.7.10870.55762709629-32828-1.197
2023-09-30BlackRock Inc5.14970.00951962917982815.2708
2023-12-31T. Rowe Price Associates, Inc.5.14620.08341961587-773251-28.2741
2023-12-31Sofinnova Ventures3.623424.4612138114900
2023-12-31Wellington Management Company LLP2.97520.0671134046-151462-11.7823
2023-12-31General Atlantic Llc2.58864.480498671000
2023-09-30State Street Corporation2.43710.008792897011368413.9441
2023-09-30Pivotal bioVenture Partners Investment Advisor LLC2.090953.7524797008150001.9181
2023-09-30Geode Capital Management, LLC1.430.0115450736092612.5842
2023-12-31Rock Springs Capital Management LP1.35124.012951502495911.8976
2023-09-30Amvescap Plc.0.95790.0166365134-30423-7.6912
2023-09-30AllianceBernstein L.P.0.95330.0261363368-20594-5.3636
2023-12-31Woodline Partners LP0.93781.23043574733347511473.2462
2023-09-30Point72 Asset Management, L.P.0.91250.1716347800301860657.0744
2023-12-31Brown Advisory Holdings Inc0.8740.1482333144110593.4336
2023-12-31NORGES BANK0.86070.0181328067165825.3235
2023-12-31Balyasny Asset Management LLC0.82870.1878315892208093193.038
Total 74.543589.638728413845+537025+1.9%

3.2. Funds holding Karuna Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31American Funds Growth Fund of Amer A5.42580.26342072609-353121-14.5573
2023-12-31Capital Group Growth Fnd of Amer Comp5.42580.26342072609-353121-14.5573
2024-02-29Vanguard Total Stock Mkt Idx Inv2.65740.02061015116-2505-0.2462
2024-02-29Vanguard Small Cap Index2.16390.184782660876510.9342
2023-12-31Vanguard Health Care Inv2.08470.543796328-103780-11.5297
2023-12-31American Funds New Perspective A1.78490.170368181230635781.5962
2023-12-31Capital Group New Perspective Comp1.78490.170368181230635781.5962
2023-12-31T. Rowe Price US Mid-Cap Growth Equity1.69770.6756648500233503.7351
2023-12-31T. Rowe Price Mid-Cap Growth1.69770.6778648500233503.7351
2023-12-31American Funds IS® Growth 11.480.455356535016579741.4956
2023-12-31Capital Group Growth Composite1.480.455356535016579741.4956
2024-02-29Vanguard Small Cap Value Index Inv1.47590.332956379428060.5002
2024-02-29BlackRock Event Driven Equity Instl1.44993.0808553863271195.1484
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.38690.16352977513920.2634
2023-12-31T. Rowe Price Health Sciences1.23491.0149471717-270478-36.443
2023-12-31American Funds SMALLCAP World A1.07620.1808411109-67643-14.129
2023-12-31T. Rowe Price Capital Appreciation0.84990.182324667-53900-14.2379
2023-12-31T. Rowe Price New Horizons0.83810.4095320132-366772-53.3949
2023-12-31US Small-Cap Growth II Equity Comp0.83810.4081320132-366772-53.3949
2023-12-31Capital Group Fundamental Invtrs Comp0.73090.070727918610049756.2413
Total 37.56369.722414348969-807619-5.6%

3.3. Insider Transactions

Insiders are holding 4.986% of the shares of Karuna Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-08Stephen K BrannanSELL5000318.34
2024-02-08Stephen K BrannanSELL5000316.13
2024-01-08Stephen K BrannanSELL15000316.81
2023-12-08Stephen K BrannanSELL10000202.37
2023-11-08Stephen K BrannanSELL5000177.85
2023-10-09Stephen K BrannanSELL5000173.24
2023-09-08Stephen K BrannanSELL5000184.04
2023-09-01Jeffrey M JonasSELL13809187.93
2023-08-22Troy A IgnelziSELL1500175.12
2023-08-01Jeffrey M JonasSELL13810195.81
2023-07-03Laurie J OlsonSELL1000215.65
2023-05-23Troy A IgnelziSELL9000223.41
2023-04-20Andrew Craig MillerSELL15000200.13
2023-04-18Andrew Craig MillerSELL30000200.16
2023-04-10Stephen K BrannanSELL5000176.88

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Karuna Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.7820.838-313%4.085-144%1.522-217%1.564-214%
Book Value Per Share--32.83435.892-9%20.742+58%16.674+97%15.994+105%
Current Ratio--19.30636.136-47%27.726-30%56.558-66%59.307-67%
Debt To Asset Ratio--0.0610.040+53%0.044+39%0.180-66%0.172-64%
Debt To Equity Ratio--0.0650.042+55%0.046+41%0.029+124%0.028+131%
Dividend Per Share----0%-0%-0%-0%
Eps---2.980-2.838-5%-1.809-39%-1.265-58%-1.215-59%
Free Cash Flow Per Share---2.928-2.544-13%-1.497-49%-1.077-63%-1.034-65%
Free Cash Flow To Equity Per Share---2.4080.619-489%4.104-159%1.575-253%1.494-261%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---184.790--------
Intrinsic Value_10Y_min---155.661--------
Intrinsic Value_1Y_max---8.075--------
Intrinsic Value_1Y_min---7.926--------
Intrinsic Value_3Y_max---32.221--------
Intrinsic Value_3Y_min---30.601--------
Intrinsic Value_5Y_max---65.962--------
Intrinsic Value_5Y_min---60.539--------
Market Cap12599275119.000+4%12090460443.0008442904784.250+43%6443553422.250+88%4813913985.300+151%4584679986.000+164%
Net Profit Margin----32.9060%-219.7970%-50.5780%-48.1700%
Operating Margin----41.8170%-257.1050%-59.8230%-56.9740%
Operating Ratio---42.067-100%258.750-100%60.252-100%57.382-100%
Pb Ratio10.045+4%9.6406.256+54%9.129+6%6.470+49%6.162+56%
Pe Ratio-27.673-4%-26.555-19.491-27%-22.983-13%-32.537+23%-30.988+17%
Price Per Share329.830+4%316.510221.023+43%168.683+88%126.021+151%120.020+164%
Price To Free Cash Flow Ratio-28.159-4%-27.022-22.660-16%-28.531+6%-42.426+57%-40.406+50%
Price To Total Gains Ratio-185.063-4%-177.589-86.409-51%-79.827-55%-137.407-23%-137.407-23%
Quick Ratio--34.41661.889-44%43.810-21%87.292-61%88.770-61%
Return On Assets---0.085-0.075-13%-0.098+15%-0.077-9%-0.078-9%
Return On Equity---0.091-0.078-14%-0.103+14%-0.063-31%-0.064-29%
Total Gains Per Share---1.7820.838-313%4.085-144%1.522-217%1.564-214%
Usd Book Value--1254235000.0001371062250.000-9%792322500.000+58%636938550.000+97%610968619.048+105%
Usd Book Value Change Per Share---1.7820.838-313%4.085-144%1.522-217%1.564-214%
Usd Book Value Per Share--32.83435.892-9%20.742+58%16.674+97%15.994+105%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---2.980-2.838-5%-1.809-39%-1.265-58%-1.215-59%
Usd Free Cash Flow---111858000.000-97184000.000-13%-57178750.000-49%-41135700.000-63%-39510000.000-65%
Usd Free Cash Flow Per Share---2.928-2.544-13%-1.497-49%-1.077-63%-1.034-65%
Usd Free Cash Flow To Equity Per Share---2.4080.619-489%4.104-159%1.575-253%1.494-261%
Usd Market Cap12599275119.000+4%12090460443.0008442904784.250+43%6443553422.250+88%4813913985.300+151%4584679986.000+164%
Usd Price Per Share329.830+4%316.510221.023+43%168.683+88%126.021+151%120.020+164%
Usd Profit---113824000.000-105547000.000-7%-66952000.000-41%-47315600.000-58%-45459000.000-60%
Usd Revenue---163500.000-100%2659250.000-100%2412750.000-100%2297857.143-100%
Usd Total Gains Per Share---1.7820.838-313%4.085-144%1.522-217%1.564-214%
 EOD+5 -3MRQTTM+6 -25YOY+10 -215Y+8 -2310Y+8 -23

4.2. Fundamental Score

Let's check the fundamental score of Karuna Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-27.673
Price to Book Ratio (EOD)Between0-110.045
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than134.416
Current Ratio (MRQ)Greater than119.306
Debt to Asset Ratio (MRQ)Less than10.061
Debt to Equity Ratio (MRQ)Less than10.065
Return on Equity (MRQ)Greater than0.15-0.091
Return on Assets (MRQ)Greater than0.05-0.085
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Karuna Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5075.401
Ma 20Greater thanMa 50319.979
Ma 50Greater thanMa 100317.671
Ma 100Greater thanMa 200263.309
OpenGreater thanClose329.830
Total4/5 (80.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -3,2901,675-1,615-2,027-3,642713-2,9293,140211



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,336,209
Total Liabilities81,974
Total Stockholder Equity1,254,235
 As reported
Total Liabilities 81,974
Total Stockholder Equity+ 1,254,235
Total Assets = 1,336,209

Assets

Total Assets1,336,209
Total Current Assets1,315,313
Long-term Assets20,896
Total Current Assets
Cash And Cash Equivalents 185,823
Short-term Investments 1,076,990
Net Receivables 4,900
Inventory 32,831
Other Current Assets 14,769
Total Current Assets  (as reported)1,315,313
Total Current Assets  (calculated)1,315,313
+/-0
Long-term Assets
Property Plant Equipment 20,514
Long-term Assets Other 382
Long-term Assets  (as reported)20,896
Long-term Assets  (calculated)20,896
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities68,129
Long-term Liabilities13,845
Total Stockholder Equity1,254,235
Total Current Liabilities
Short-term Debt 2,843
Accounts payable 6,783
Other Current Liabilities 16,894
Total Current Liabilities  (as reported)68,129
Total Current Liabilities  (calculated)26,520
+/- 41,609
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt13,845
Long-term Liabilities  (as reported)13,845
Long-term Liabilities  (calculated)13,845
+/-0
Total Stockholder Equity
Common Stock4
Retained Earnings -997,887
Accumulated Other Comprehensive Income 211
Other Stockholders Equity 2,251,907
Total Stockholder Equity (as reported)1,254,235
Total Stockholder Equity (calculated)1,254,235
+/-0
Other
Capital Stock4
Cash and Short Term Investments 1,262,813
Common Stock Shares Outstanding 37,781
Current Deferred Revenue41,609
Liabilities and Stockholders Equity 1,336,209
Net Debt -169,135
Net Invested Capital 1,254,235
Net Working Capital 1,247,184
Property Plant and Equipment Gross 23,620
Short Long Term Debt Total 16,688



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
> Total Assets 
0
0
0
92,479
85,400
79,357
164,227
393,024
389,718
377,816
364,436
347,625
593,264
577,188
540,098
527,671
474,474
433,556
1,228,412
1,163,334
1,516,168
1,472,103
1,385,097
1,336,209
1,336,2091,385,0971,472,1031,516,1681,163,3341,228,412433,556474,474527,671540,098577,188593,264347,625364,436377,816389,718393,024164,22779,35785,40092,479000
   > Total Current Assets 
0
0
0
92,218
85,132
79,048
163,928
392,706
386,668
374,856
361,220
344,599
590,018
567,098
529,442
517,334
464,639
424,181
1,219,678
1,154,769
1,507,759
1,451,947
1,365,397
1,315,313
1,315,3131,365,3971,451,9471,507,7591,154,7691,219,678424,181464,639517,334529,442567,098590,018344,599361,220374,856386,668392,706163,92879,04885,13292,218000
       Cash And Cash Equivalents 
0
0
0
85,526
84,275
10,495
54,144
208,929
190,645
133,873
44,787
53,048
353,685
345,649
252,221
206,953
176,203
136,096
628,317
248,329
562,660
263,603
184,471
185,823
185,823184,471263,603562,660248,329628,317136,096176,203206,953252,221345,649353,68553,04844,787133,873190,645208,92954,14410,49584,27585,526000
       Short-term Investments 
0
0
0
4,983
0
64,804
107,461
180,468
192,846
233,712
300,110
269,282
217,610
197,979
246,682
287,038
266,984
271,318
563,717
875,715
909,761
1,172,907
1,157,039
1,076,990
1,076,9901,157,0391,172,907909,761875,715563,717271,318266,984287,038246,682197,979217,610269,282300,110233,712192,846180,468107,46164,80404,983000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,750
0
4,750
81
57
0
0
4,900
4,900
4,9004,9000057814,75001,750000000000000000
       Other Current Assets 
0
0
0
23
46
63
223
485
317
255
262
1,088
535
783
697
708
1,946
1,296
2,682
2,343
35,338
6,693
11,492
14,769
14,76911,4926,69335,3382,3432,6821,2961,9467086977835351,088262255317485223634623000
   > Long-term Assets 
0
0
0
261
268
309
299
318
3,050
2,960
3,216
3,026
3,246
10,090
10,656
10,337
9,835
9,375
8,734
8,565
8,409
20,156
19,700
20,896
20,89619,70020,1568,4098,5658,7349,3759,83510,33710,65610,0903,2463,0263,2162,9603,050318299309268261000
       Property Plant Equipment 
0
0
0
138
145
186
176
195
2,893
2,803
3,059
2,869
1,979
9,100
9,887
9,545
9,071
8,659
8,050
7,875
7,930
19,617
19,318
20,514
20,51419,31819,6177,9307,8758,0508,6599,0719,5459,8879,1001,9792,8693,0592,8032,893195176186145138000
       Other Assets 
0
0
0
0
123
123
123
123
157
157
157
2,577
1,267
990
769
792
764
716
684
690
0
539
0
0
0053906906847167647927699901,2672,5771571571571231231231230000
> Total Liabilities 
0
0
0
909
124,165
126,346
1,697
3,108
4,777
6,013
7,177
8,694
8,350
16,850
21,770
25,645
20,786
28,147
44,457
37,096
28,033
52,540
62,781
81,974
81,97462,78152,54028,03337,09644,45728,14720,78625,64521,77016,8508,3508,6947,1776,0134,7773,1081,697126,346124,165909000
   > Total Current Liabilities 
0
0
0
807
2,165
2,275
1,533
2,958
2,652
4,069
5,119
6,853
6,628
10,309
15,779
20,213
15,923
23,868
40,745
33,946
25,237
38,603
48,968
68,129
68,12948,96838,60325,23733,94640,74523,86815,92320,21315,77910,3096,6286,8535,1194,0692,6522,9581,5332,2752,165807000
       Short-term Debt 
0
0
0
0
18
55
56
58
624
674
827
844
862
1,963
2,132
2,175
2,219
2,262
2,278
2,282
2,067
1,977
1,796
2,843
2,8431,7961,9772,0672,2822,2782,2622,2192,1752,1321,963862844827674624585655180000
       Accounts payable 
0
0
0
269
854
960
158
547
603
773
1,145
865
1,298
1,966
1,989
1,939
1,478
3,920
15,716
2,379
476
1,102
2,939
6,783
6,7832,9391,1024762,37915,7163,9201,4781,9391,9891,9661,2988651,145773603547158960854269000
       Other Current Liabilities 
0
0
0
538
1,293
1,260
1,319
2,353
1,425
2,622
3,147
5,144
4,468
6,380
11,658
16,099
12,226
17,686
22,751
29,285
22,694
35,524
104
16,894
16,89410435,52422,69429,28522,75117,68612,22616,09911,6586,3804,4685,1443,1472,6221,4252,3531,3191,2601,293538000
   > Long-term Liabilities 
0
0
0
102
122,000
124,071
164
150
2,125
1,944
2,058
1,841
1,722
6,541
5,991
5,432
4,863
4,279
3,712
3,150
2,796
13,937
13,813
13,845
13,84513,81313,9372,7963,1503,7124,2794,8635,4325,9916,5411,7221,8412,0581,9442,125150164124,071122,000102000
       Other Liabilities 
0
0
0
0
194
179
164
150
0
0
0
0
104
104
104
104
104
104
104
104
0
104
0
0
00104010410410410410410410410400001501641791940000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
600
300
0
0
0
0
0
0
0
0
0
0
0000000000300600000000000000
> Total Stockholder Equity
-13,368
0
0
91,570
-38,765
-46,989
162,530
389,916
384,941
371,803
357,259
338,931
584,914
560,338
518,328
502,026
453,688
405,409
1,183,955
1,126,238
1,488,135
1,419,563
1,322,316
1,254,235
1,254,2351,322,3161,419,5631,488,1351,126,2381,183,955405,409453,688502,026518,328560,338584,914338,931357,259371,803384,941389,916162,530-46,989-38,76591,57000-13,368
   Common Stock
0
0
0
1
0
-1
2
3
3
3
3
3
3
3
3
3
3
3
3
3
4
4
4
4
444433333333333332-101000
   Retained Earnings Total Equity000-661,781-564,207-487,995-411,032-346,089-287,871-259,911-208,979-174,563-144,06600000000000
   Accumulated Other Comprehensive Income 
0
0
0
-7
0
71
50
5
1,571
897
370
39
9
-5
-35
-497
-2,535
-2,995
-3,698
-3,290
-1,615
-3,642
-2,929
211
211-2,929-3,642-1,615-3,290-3,698-2,995-2,535-497-35-59393708971,571550710-7000
   Capital Surplus 
0
0
0
0
4,795
11,640
230,216
465,420
467,537
0
0
482,955
759,465
769,319
778,271
790,391
802,309
819,433
1,675,645
1,693,732
2,151,527
0
0
0
0002,151,5271,693,7321,675,645819,433802,309790,391778,271769,319759,465482,95500467,537465,420230,21611,6404,7950000
   Treasury Stock000000000000000000000000
   Other Stockholders Equity 
0
0
0
123,678
4,795
11,640
65,989
465,420
77,819
472,119
476,943
482,955
759,465
769,319
778,271
790,391
802,309
819,433
1,675,645
1,693,732
2,151,527
2,188,145
2,209,304
2,251,907
2,251,9072,209,3042,188,1452,151,5271,693,7321,675,645819,433802,309790,391778,271769,319759,465482,955476,943472,11977,819465,42065,98911,6404,795123,678000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue654
Cost of Revenue-1,701
Gross Profit-1,047-1,047
 
Operating Income (+$)
Gross Profit-1,047
Operating Expense-495,431
Operating Income-494,777-496,478
 
Operating Expense (+$)
Research Development364,101
Selling General Administrative131,330
Selling And Marketing Expenses0
Operating Expense495,431495,431
 
Net Interest Income (+$)
Interest Income61,179
Interest Expense-0
Other Finance Cost-0
Net Interest Income61,179
 
Pretax Income (+$)
Operating Income-494,777
Net Interest Income61,179
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-433,010-495,365
EBIT - interestExpense = -494,777
-433,010
-433,680
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-494,777-433,010
Earnings Before Interest and Taxes (EBITDA)-493,076
 
After tax Income (+$)
Income Before Tax-433,010
Tax Provision-670
Net Income From Continuing Ops-433,680-433,680
Net Income-433,680
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses495,431
Total Other Income/Expenses Net588-61,179
 

Technical Analysis of Karuna Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Karuna Therapeutics Inc. The general trend of Karuna Therapeutics Inc is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Karuna Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Karuna Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: .

The bearish price targets are: 321.45 > 312.78 > 296.06.

Tweet this
Karuna Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Karuna Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Karuna Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Karuna Therapeutics Inc. The current macd is 4.1539558.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Karuna Therapeutics Inc price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Karuna Therapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Karuna Therapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Karuna Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartKaruna Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Karuna Therapeutics Inc. The current adx is 32.32.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Karuna Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Karuna Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Karuna Therapeutics Inc. The current sar is 312.53.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Karuna Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Karuna Therapeutics Inc. The current rsi is 75.40. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -1/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
Karuna Therapeutics Inc Daily Relative Strength Index (RSI) ChartKaruna Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Karuna Therapeutics Inc. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Karuna Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Karuna Therapeutics Inc Daily Stochastic Oscillator ChartKaruna Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Karuna Therapeutics Inc. The current cci is 194.22.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Karuna Therapeutics Inc Daily Commodity Channel Index (CCI) ChartKaruna Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Karuna Therapeutics Inc. The current cmo is 59.61.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Karuna Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartKaruna Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Karuna Therapeutics Inc. The current willr is -0.99378882.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Karuna Therapeutics Inc Daily Williams %R ChartKaruna Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Karuna Therapeutics Inc.

Karuna Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Karuna Therapeutics Inc. The current atr is 3.08137247.

Karuna Therapeutics Inc Daily Average True Range (ATR) ChartKaruna Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Karuna Therapeutics Inc. The current obv is 16,367,336.

Karuna Therapeutics Inc Daily On-Balance Volume (OBV) ChartKaruna Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Karuna Therapeutics Inc. The current mfi is 89.19.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Karuna Therapeutics Inc Daily Money Flow Index (MFI) ChartKaruna Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Karuna Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-10-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-10-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-10-31STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-03STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-06STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-11-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-24STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-26MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-09WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-16RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-15MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Karuna Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Karuna Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5075.401
Ma 20Greater thanMa 50319.979
Ma 50Greater thanMa 100317.671
Ma 100Greater thanMa 200263.309
OpenGreater thanClose329.830
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Karuna Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Karuna Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Karuna Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Karuna Therapeutics Inc

I send you an email if I find something interesting about Karuna Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Karuna Therapeutics Inc.

Receive notifications about Karuna Therapeutics Inc in your mailbox!